Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Completed
Eyetech Pharmaceuticals
Phase 2
2002-10-01
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and
effective in slowing the leakage of fluid within the retina and thereby stabilizing or
improving vision when compared to placebo injections. A total of 176 patients will be
enrolled
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Completed
Pfizer
N/A
2004-07-01
To provide Pegaptanib sodium injection to patients with subfoveal choroidal
neovascularization (CNV) secondary to AMD, who are unable to participate in any of the
Sponsor's other clinical studies with this drug for AMD, until such time as the patient's
lesion is considered to have resolved or stabilized in the opinion of the treating
ophthalmologist, or product becomes commercially available.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
